Compare Freeport-McMoRan Inc (FCX) vs Cassava Sciences Inc (FLNA) Price & Performance

FCX trades at $71.13, down 1.98% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $72.27. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong operating cash flow of $5.61 billion in 2025 supports ongoing expansion projects amid favorable copper demand trends.

The outlook for FCX is positive, driven by robust copper demand from AI and data center growth, but risks include rising production costs and a legal investigation. Wall Street sentiment is bullish with 61% buy ratings, though the stock faces near-term resistance at $72.

FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.

Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.